Optimizing Prevention Technology Introduction ON Schedule
Global introduction of public health technologies has historically faced slow uptake and low coverage compared to commercially marketed pharmaceutical equivalents.1 Although oral pre-exposure prophylaxis (PrEP) is effective and registration is in process in several countries, country-specific implementation strategies are lagging. As ongoing clinical trials test the safety and effectiveness of the dapivirine vaginal ring for HIV prevention, leaders in the HIV prevention field must seize the opportunity now to set up networks and multidisciplinary systems that can respond to expected research results with speed and urgency to:
(a) expedite the integration of new, proven technologies into the HIV prevention package,
(b) introduce them in a way that will maximize access and use, and
(c) build a strategic and sustainable product introduction platform for the long-term.
To create a programmatic platform that optimizes the portfolio mix of ARV-based prevention and related products to meet local needs and achieve global prevention goals in the most cost effective way possible.
Sites identified in Kenya, South Africa and Zimbabwe.
Landscape analyses will synthesize existing country-specific epidemiological and programmatic information and gender analyses to inform the targeting and identification of priority populations. Some country specific information already indicates that in:
• Zimbabwe - out-of-school girls, or girls with other characteristics linked to HIV risk;
• Kenya – adolescent girls
• South Africa – adolescent girls and young women, sex workers etc.
Saiqa Mullick, Diantha Pillay, Elmari Briedenhann, Mercy Murire, Patience Shamu, Alison Kutywayo
PARTNERS AND COLLABORATORS
Core Partners: Wits RHI, FHI 360, AVAC
Primary Partners: FSG, Avenir Health (Avenir), the London School of Hygiene and Tropical Medicine (LSHTM), LVCT Health, McCann Health, and Pangaea Global AIDS/Pangaea Zimbabwe AIDS Trust (Pangaea).
Extended network of collaborating partners: USAID Global and Missions, UNAIDS, WHO, product developers, global and national HIV prevention working groups, civil society, commercial partners, donors and others